Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors

Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors

Although non-small cell lung cancer (NSCLC) patients benefit from standard taxane-platin chemotherapy, many relapse, developing drug resistance. We established preclinical taxane-platin-chemoresistance models and identified a 35-gene resistance signature, which was associated with poor recurrence-fr...

Full description

Bibliographic Details
Main Authors: Maithili P. Dalvi, Lei Wang, Rui Zhong, Rahul K. Kollipara, Hyunsil Park, Juan Bayo, Paul Yenerall, Yunyun Zhou, Brenda C. Timmons, Jaime Rodriguez-Canales, Carmen Behrens, Barbara Mino, Pamela Villalobos, Edwin R. Parra, Milind Suraokar, Apar Pataer, Stephen G. Swisher, Neda Kalhor, Natarajan V. Bhanu, Benjamin A. Garcia, John V. Heymach, Kevin Coombes, Yang Xie, Luc Girard, Adi F. Gazdar, Ralf Kittler, Ignacio I. Wistuba, John D. Minna, Elisabeth D. Martinez
Format: Article
Language:English
Published: Elsevier 2017-05-01
Series:Cell Reports
Subjects:
Jumonji demethylases
JIB-04
GSK-J4
drug resistance
taxane-platin chemotherapy
KDM
demethylase inhibitors
histone methylation
histone demethylases
lung cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124717306071

Internet

http://www.sciencedirect.com/science/article/pii/S2211124717306071

Similar Items